非布司他上市了没？

Is it on the market? Febuxostat is a xanthine oxidase (XO) inhibitor that was approved for marketing in Japan in early 2004. In April 2008, the European Union first approved the marketing of febuxostat tablets, with specifications of 80 mg and 120 mg, and the trade name "Adenuric". It is used to treat chronic hyperuricemia with uric acid deposition (including patients with gout stones and/or gouty arthritis, or patients with a history of this). The FDA approved Febuxostat tablets for marketing in February 2009 for the long-term control of hyperuricemia in patients with gout. It was approved to be listed in China in 2013.

Febuxostat is a xanthine oxidase (XO) inhibitor that binds to xanthine oxidase through a non-competitive mechanism, inhibits xanthine oxidase activity, inhibits the production of uric acid, and achieves the purpose of reducing acidity. Therefore, it is suitable for the long-term treatment of hyperuricemia with gout symptoms. Not recommended for asymptomatic hyperuricemia. Febuxostat is a newly developed drug. At the same dose, febuxostat has a stronger effect in reducing blood uric acid. Therefore, when it comes to the choice of gout acid-lowering drugs, many patients prefer febuxostat.

The recommended oral dose of febuxostat tablets is 40 mg or 80 mg once daily. The recommended starting dose of febuxostat tablets is 40 mg once daily. If the blood uric acid level is still not less than 6 mg/dl (approximately 360 µmol/L) after 2 weeks, it is recommended that the dose be increased to 80 mg once a day. Food and antacid effects do not need to be considered when administering the drug.

Special populations: Patients with hepatic impairment: Patients with mild or moderate hepatic impairment (Child-Pugh A, B) do not need to adjust the dosage. The efficacy and safety of febuxostat in patients with severe hepatic insufficiency (Child-Pugh class C) have not been studied, so febuxostat should be used with caution in these patients. Patients with renal insufficiency: Patients with mild or moderate renal insufficiency (Clcr30-89 ml/min) do not need to adjust the dose. The recommended starting dose of febuxostat is 40 mg once daily. If the blood uric acid level is still not less than 6 mg/dl after 2 weeks, it is recommended that the dose be increased to 80 mg once a day. There are insufficient study data in patients with severe renal insufficiency (Clcr <30ml/min), so febuxostat should be used with caution in these patients. Uric acid level Two weeks after starting treatment, it can be assessed whether the blood uric acid level has reached the target value (less than 6mg/dl).